Escherichia coli ST131 Drives Carbapenem Use for E. coli Bloodstream Infections
Open Access
- 6 March 2026
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 83 (1) , e27-e37
Abstract
Background: Ceftriaxone-resistant Escherichia coli infections are increasingly common, partially because of the emergence of E. coli sequence type 131 (ST131), including its subclade C2/H30Rx, which produce extended-spectrum β-lactamases. Methods: A prospective cohort including 14 US sites, which enrolled monomicrobial ceftriaxone-resistant and susceptible E. coli bloodstream infection (BSI) cases in a 1:1 ratio, was used to compare ST131 versus non-ST131 E. coli BSI, with specific attention to E. coli ST131 C2/H30Rx. Desirability of outcome ranking was determined at 30 days after infection onset. Results: This analysis included 282 patients with E. coli BSI; 43% (121/282) were E. coli ST131 and 23% (66/282) belonged to the C2/H30Rx subclade. Resistance to ceftriaxone was present in 79% (96/121) ST131, 86% (57/66) E. coli ST131 C2/H30Rx, and 27% (43/161) E. coli non-ST131. Compared to patients with non-ST131 E. coli BSI, patients with ST131 BSI were older (median 70 years, [Q1 62, Q3 76] years vs 65 years, [51, 74]; P = .005) and more often admitted from long-term care facilities (21/121 [17%] vs 7/161 [4%], P < .001). Overall and empiric carbapenem use was more frequent in the treatment of patients with ST131 BSI compared with non-ST131 BSI (overall 89/121 [74%] vs 50/161 [31%]; empiric: 58/121 [48%] vs 31/161 [19%], P < .001). Desirability of outcome ranking outcomes were similar between groups. Conclusions: Most ceftriaxone-resistant E. coli from US patients with E. coli BSI belong to ST131, particularly E. coli ST131 C2/H30Rx, serving as an important driver of carbapenem use.Keywords
Funding Information
- National Institutes of Health
- National Institute of Allergy and Infectious Diseases (UM1AI104681)
- National Institute of Allergy and Infectious Diseases (UM1AI104681)
- National Institute of Allergy and Infectious Diseases (UM1AI104681)
- National Institute of Allergy and Infectious Diseases (R01AI143910)
- Merck KGaA (# 60823)
This publication has 34 references indexed in Scilit:
- Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream InfectionsNew England Journal of Medicine, 2025
- Evolution of extended-spectrum β-lactamase-producing ST131 Escherichia coli at a single hospital over 15 yearsScientific Reports, 2024
- Transmission of Carbapenem-Resistant Klebsiella pneumoniae in US HospitalsClinical Infectious Diseases, 2022
- Prevalence and characteristics of multidrug-resistant Escherichia coli sequence type ST131 at two academic centers in Boston and Minneapolis, USAAmerican Journal of Infection Control, 2022
- AMRFinderPlus and the Reference Gene Catalog facilitate examination of the genomic links among antimicrobial resistance, stress response, and virulenceScientific Reports, 2021
- Hospital-diagnosed infections with Escherichia coli clonal group ST131 are mostly acquired in the communityScientific Reports, 2021
- Effect of C-Reactive Protein–Guided Antibiotic Treatment Duration, 7-Day Treatment, or 14-Day Treatment on 30-Day Clinical Failure Rate in Patients With Uncomplicated Gram-Negative BacteremiaJAMA, 2020
- An Escherichia coli ST131 pangenome atlas reveals population structure and evolution across 4,071 isolatesScientific Reports, 2019
- Self-reported risk factors for having Escherichia coli sequence type 131 or its H30 subclone among US Veterans with a clinical E. coli isolateEpidemiology and Infection, 2018
- Extensive Household Outbreak of Urinary Tract Infection and Intestinal Colonization due to Extended-Spectrum β-Lactamase–Producing Escherichia coli Sequence Type 131Clinical Infectious Diseases, 2015